Common antibiotics are failing against everyday infections in Indian hospitals, and even the powerful drugs doctors keep in reserve for the sickest patients are losing their punch. That is the warning in a new ICMR report, released in New Delhi on Wednesday, 18 November 2026.
The ICMR Antimicrobial Resistance Surveillance and Research Network (AMRSN) Annual Report 2025 is based on 1,13,008 positive laboratory samples from 30 large, specialised hospitals in 2025. For the first time, it also covers 34 smaller, secondary-care hospitals, including 12 district hospitals, which added 20,529 samples.
What the report found
Four bacteria dominated the samples from large hospitals. Escherichia coli, or E. coli, accounted for 24.4 per cent, followed by Klebsiella pneumoniae at 16.9 per cent, Pseudomonas aeruginosa at 12.2 per cent and Acinetobacter baumannii at 9.5 per cent.
The problem is particularly serious with E. coli. Only 18.4 per cent of tested samples responded to cefotaxime and 24.7 per cent to ceftazidime, two widely used antibiotics. Just 9 per cent responded to ciprofloxacin, a medicine many Indians will recognise from prescriptions for urinary infections and diarrhoea.
Klebsiella pneumoniae presents a similar challenge. In 2025, only 36.5 to 40.4 per cent of tested samples responded to carbapenems, the powerful antibiotics doctors rely on when other medicines fail, and the response was even lower in intensive-care units.

The 91 per cent figure that should worry everyone
The most alarming finding concerns Acinetobacter baumannii: 91.1 per cent of tested samples were resistant to carbapenems, leaving doctors with very few treatment options, especially in ICUs. The report also found that 56.8 per cent of tested Staphylococcus aureus samples were resistant to methicillin, and that diarrhoea-causing bacteria barely responded to ciprofloxacin at all: just 0.7 per cent of diarrhoeal E. coli samples responded, and only 7.5 per cent of Shigella flexneri samples.
Resistance is reaching smaller hospitals too
The first-time inclusion of 34 secondary-care hospitals is one of the most important parts of this year’s report. It shows that resistance to commonly used antibiotics is a concern at every level of healthcare, not just in large specialised centres.
The gradient is steep. Ceftriaxone susceptibility in E. coli fell from 39.8 per cent in the largest hospitals to 28.0 per cent in mid-level hospitals and just 11.5 per cent in the smallest facilities. Meropenem showed the same slide, from 80.3 per cent to 77.5 per cent and then 67.1 per cent. Resistance to third-generation cephalosporins is now very high even in secondary-care hospitals, though carbapenem resistance largely remains a problem of the bigger hospitals for now.
Why it matters
This report changes what happens at a hospital bedside tonight. When a patient arrives with a urinary infection or a wound infection, the doctor’s first-choice antibiotic may already be a coin toss. Treatment then becomes a slower, costlier process of tests, second-line drugs and longer stays.
A separate ICMR-linked study across 20 hospitals between April 2022 and April 2025 underlines the danger. It analysed 1,59,336 patients and found more than 61 per cent of confirmed Gram-negative infections were resistant to carbapenems. Mortality from bloodstream infections was around 39 per cent for resistant E. coli and about 51 per cent for resistant Acinetobacter, and antibiotic costs for resistant infections ran 1.1 to 2 times higher.
Put the two studies together and the picture is clear. India is not facing a distant threat. As Dr Neha Rastogi Panda, senior consultant in infectious diseases at Fortis Hospital, Gurugram, told Health and Me, antibiotic resistance is no longer a distant threat, it is affecting patients and families across India right now. The 2025 report adds that the problem has now reached district hospitals too. In November 2025, the Union government launched the National Action Plan on Antimicrobial Resistance 2.0, covering 2025 to 2029. What the numbers demand now is action on the ground: better diagnostics, stricter infection control, and far more careful use of antibiotics by doctors and patients alike.
What you can do
- Never self-medicate with antibiotics. Do not buy them over the counter for a cold, fever or loose motions, and never stop a prescribed course midway.
- Ask for a test, not just a tablet. A culture and sensitivity test identifies the bacteria and shows which antibiotics are likely to work.
- Protect the last-resort drugs. Carbapenems should be reserved for serious infections where other medicines have failed.
- Prevention is treatment. Handwashing, clean equipment and safe food and water reduce infections, so fewer antibiotics are needed.
FAQs
What is antimicrobial resistance?
It is the ability of bacteria to survive medicines designed to kill them, so infections last longer and carry a higher risk of death.
Is antibiotic resistance only a big-hospital problem?
No. The 2025 report covered 34 secondary-care hospitals for the first time and found high resistance there too: ceftriaxone worked against only 11.5 per cent of E. coli samples in the smallest hospitals.
What should I do if my doctor prescribes an antibiotic?
Take it exactly as prescribed and finish the full course. Do not share leftover antibiotics with family members. If symptoms do not improve, go back to the doctor rather than switching medicines on your own.
The ICMR report is a warning, not a verdict. Antibiotics still save millions of lives in India every year, but the margin is shrinking. Whether the next report tells a better story depends on how carefully the country uses these medicines from today onwards.

